Gilead Sciences (GILD) Compassionate Use Remdesivir Data Is an Incremental Positive - BMO Capital
Tweet Send to a Friend
BMO Capital analyst Matthew Luchini reiterated an Outperform rating and $79.00 price target on Gilead Sciences (NASDAQ: GILD) after NEJM ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
